Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate : Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3)

Atsumi, Tatsuya; Tanaka, Yoshiya; Matsubara, Tsukasa; Amano, Koichi; Ishiguro, Naoki; Sugiyama, Eiji; Yamaoka, Kunihiro; Westhovens, Rene; Ching, Daniel W. T.; Messina, Osvaldo Daniel; Burmester, Gerd R.; Bartok, Beatrix; Pechonkina, Alena; Kondo, Akira; Yin, Zhaoyu; Guo, Ying; Tasset, Chantal; Sundy, John S.; Takeuchi, Tsutomu

Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate : Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3)

Atsumi, Tatsuya; Tanaka, Yoshiya; Matsubara, Tsukasa et al.

Modern rheumatology, 2022, 32(2), 273-283

Permalink : https://hdl.handle.net/2115/85673

このアイテムのアクセス数:458件（2026-01-16 14:56 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
https://doi.org/10.1093/mr/roab021

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	metadata only access
URI	https://hdl.handle.net/2115/85673
タイトル	Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate : Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3)
著者	Atsumi, Tatsuya ; Tanaka, Yoshiya ; Matsubara, Tsukasa ; Amano, Koichi ; Ishiguro, Naoki ; Sugiyama, Eiji ; Yamaoka, Kunihiro ; Westhovens, Rene ; Ching, Daniel W. T. ; Messina, Osvaldo Daniel ; Burmester, Gerd R. ; Bartok, Beatrix ; Pechonkina, Alena ; Kondo, Akira ; Yin, Zhaoyu ; Guo, Ying ; Tasset, Chantal ; Sundy, John S. ; Takeuchi, Tsutomu
e-Rad_Researcher 20301905 著者名 Atsumi, Tatsuya
e-Rad_Researcher 30248562 著者名 Tanaka, Yoshiya
著者名 Matsubara, Tsukasa
著者名 Amano, Koichi
著者名 Ishiguro, Naoki
著者名 Sugiyama, Eiji
著者名 Yamaoka, Kunihiro
著者名 Westhovens, Rene
著者名 Ching, Daniel W. T.
著者名 Messina, Osvaldo Daniel
著者名 Burmester, Gerd R.
著者名 Bartok, Beatrix
著者名 Pechonkina, Alena
著者名 Kondo, Akira
著者名 Yin, Zhaoyu
著者名 Guo, Ying
著者名 Tasset, Chantal
著者名 Sundy, John S.
著者名 Takeuchi, Tsutomu
言語	英語
キーワード	Filgotinib
	Janus kinase
	Japanese
	phase 3 clinical trials
	rheumatoid arthritis
発行日	2022-03
出版者	Oxford University Press
収録物名	Modern rheumatology
巻(号)	32(2)
ページ	273-283
抄録	Objectives To evaluate the efficacy and safety of filgotinib for Japanese patients with rheumatoid arthritis (RA) and limited or no prior methotrexate (MTX) exposure. Methods Data up to 24 weeks were analysed for 71 Japanese patients from a 52-week global Phase 3 study. Patients with RA and limited or no prior MTX exposure were randomised in a 2:1:1:2 ratio to filgotinib 200 mg plus MTX, filgotinib 100 mg plus MTX, filgotinib 200 mg, or MTX. Maximum MTX dose was 15 mg/week. Primary endpoint was proportion achieving 20% improvement in American College of Rheumatology criteria (ACR20) at Week 24. Results Week 24 ACR20 rates in Japanese patients were 82.6%, 90.9%, 83.3%, and 80.0% for filgotinib 200 mg plus MTX, filgotinib 100 mg plus MTX, filgotinib 200 mg, and MTX, respectively. Greater ACR20 rates with filgotinib vs MTX occurred at Week 2. Greater proportions receiving filgotinib vs MTX achieved DAS28-CRP Conclusions While Week 24 ACR20 rates were similar, filgotinib provided faster responses and higher remission rates vs MTX. In Japanese patients with RA and limited or no prior MTX exposure, filgotinib was generally well tolerated.
資源タイプ	学術雑誌論文
出版タイプ	Version of Record
PISSN	1439-7595
関連情報 (isIdenticalTo)	出版社版DOI https://doi.org/10.1093/mr/roab021